Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Freeline Therapeutics Holdings Plc Adss (FRLN)

Freeline Therapeutics Holdings Plc Adss (FRLN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Freeline Therapeutics Holdings Plc Adss SYCAMORE HOUSE GUNNELS WOOD ROAD STEVENAGE HERTFORDSHIRE X0 SG1 2BP GBR

www.freeline.life P: 44-0-14-3890-6870

Description:

Freeline Therapeutics Holdings plc is a clinical-stage biotechnology company. It is focused on AAV-based gene therapy targeting the liver. The company operates principally in Germany and the U.S. Freeline Therapeutics Holdings plc is headquartered in the U.K.

Key Statistics

Overview:

Market Capitalization, $K 28,129
Enterprise Value, $K -19,151
Shares Outstanding, K 4,341
Annual Sales, $ 0 K
Annual Net Income, $ -88,970 K
Last Quarter Sales, $ 10 K
Last Quarter Net Income, $ -12,090 K
EBIT, $ -20,080 K
EBITDA, $ -96,710 K
60-Month Beta 0.66
% of Insider Shareholders 1.90%
% of Institutional Shareholders 46.26%
Float, K 4,258
% Float 98.10%
Short Volume Ratio 0.04

Growth:

1-Year Return -20.00%
3-Year Return -97.26%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.18 on 12/01/23
Next Earnings Date 04/02/24
Earnings Per Share ttm -5.90
EPS Growth vs. Prev Qtr 14.29%
EPS Growth vs. Prev Year 93.97%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-15 on 05/12/23

FRLN Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -150.46%
Return-on-Assets % -97.01%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales 45.25
Price/Cash Flow N/A
Price/Book 0.94
Book Value/Share 6.92
Interest Coverage -1.75
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar